Entity

Time filter

Source Type

BERKELEY, CA, United States

Coffman R.L.,Dynavax Technologies Corporation | Sher A.,National Institute of Allergy and Infectious Diseases | Seder R.A.,National Institute of Allergy and Infectious Diseases
Immunity | Year: 2010

Adjuvants enhance immunity to vaccines and experimental antigens by a variety of mechanisms. In the past decade, many receptors and signaling pathways in the innate immune system have been defined and these innate responses strongly influence the adaptive immune response. The focus of this review is to delineate the innate mechanisms by which adjuvants mediate their effects. We highlight how adjuvants can be used to influence the magnitude and alter the quality of the adaptive response in order to provide maximum protection against specific pathogens. Despite the impressive success of currently approved adjuvants for generating immunity to viral and bacterial infections, there remains a need for improved adjuvants that enhance protective antibody responses, especially in populations that respond poorly to current vaccines. However, the larger challenge is to develop vaccines that generate strong T cell immunity with purified or recombinant vaccine antigens. © 2010 Elsevier Inc. Source


Patent
Dynavax Technologies Corporation | Date: 2014-07-18

The invention provides methods for treating asthma by using multiple rounds of administration of ISS over a period of time to confer long term disease modification.


Patent
Dynavax Technologies Corporation | Date: 2015-04-23

Provided herein are human Toll-like receptor 8 (TLR8)-expressing transgenic animals and methods of use thereof.


Patent
Dynavax Technologies Corporation | Date: 2014-11-25

The application relates to compositions and methods of regulating an immune response comprising inhibitors of TLR7 and/or TLR9, such as immunoregulatory polynucleotides and/or immunoregulatory compounds. The application also relates to compositions and methods for predicting and/or determining responsiveness of a disease to treatment comprising inhibitors of TLR7 and/or TLR9.


Patent
Dynavax Technologies Corporation | Date: 2014-10-20

The invention provides immunomodulatory polynucleotides and methods for immunomodulation of individuals using the immunomodulatory polynucleotides.

Discover hidden collaborations